XOLEGEL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XOLEGEL (XOLEGEL).
Cholestyramine, the active ingredient in XOLEGEL, is a bile acid sequestrant. It binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces. This prevents enterohepatic recirculation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver, thereby lowering serum low-density lipoprotein (LDL) cholesterol.
| Metabolism | Not metabolized; acts locally in the gastrointestinal tract and is excreted unchanged in the feces. |
| Excretion | Following topical application, negligible systemic absorption occurs; any absorbed fraction is primarily eliminated via renal excretion as unchanged drug and metabolites. Biliary/fecal excretion is minimal. |
| Half-life | The terminal elimination half-life is approximately 2.5 hours in adults based on intravenous data, but clinical relevance is minimal due to negligible systemic absorption after topical use. |
| Protein binding | Approximately 95-98% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 17-20 L (0.24-0.29 L/kg) based on intravenous data, indicating distribution into total body water. |
| Bioavailability | Systemic bioavailability after topical application is less than 1% of administered dose due to minimal percutaneous absorption. |
| Onset of Action | Onset of action occurs within 2-4 hours after topical application, with visible reduction in inflammatory lesions and pruritus. |
| Duration of Action | Duration of action persists for approximately 12-24 hours after a single application, with twice-daily dosing recommended to maintain clinical effect. |
| Molecular Weight | 493.94 |
| Action Class | Proton pump inhibitors |
| Brand Substitutes | Topp 40 Tablet, Panplus 40 Tablet, Aciban 40 Tablet, Duopep 40 Tablet, Pazom 40mg Tablet, Panfirst 40mg Injection, Troypanto 40mg Injection, Zepoxin 40mg Injection, P-Ppi Injection, Pantodac IV Injection |
Apply a thin layer to affected areas once daily. Maximum 60 g per week. Do not use on the face, axillae, or groin. Not for ophthalmic, oral, or intravaginal use.
| Dosage form | GEL |
| Renal impairment | No dosage adjustment required in renal impairment. |
| Liver impairment | No dosage adjustment required in hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. |
| Geriatric use | No specific dosage adjustment recommended; use with caution due to age-related skin fragility. |
| 1st trimester | No adequate studies in pregnant women. Use only if potential benefit justifies risk to fetus. Topical minocycline is minimally absorbed. |
| 2nd trimester | No evidence of fetal harm in animal studies. Systemic absorption is low. Consider risk-benefit. |
| 3rd trimester | Avoid use near term due to theoretical risk of bone/teeth discoloration in fetus, though absorption is minimal. |
Clinical note
Comprehensive clinical and safety monograph for XOLEGEL (XOLEGEL).
| Placental transfer | Minocycline crosses the placenta. Oral administration leads to fetal plasma levels approximately 25-50% of maternal levels. Topical application results in low systemic absorption, thus placental transfer is expected to be minimal. |
| Breastfeeding | Minocycline is excreted into breast milk in small amounts after oral administration. Topical application likely results in negligible systemic absorption. However, due to risk of dental discoloration and bone growth inhibition in infants, use with caution; consider alternative therapy. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to minocycline or any tetracyclineUse in children under 8 years of age (risk of permanent tooth discoloration)
| Precautions | Hyperchloremic acidosis may occur, especially in patients with renal impairment or those receiving concurrent sodium loads, May interfere with absorption of fat-soluble vitamins (A, D, E, K) and folic acid; supplementation may be needed, May bind other drugs, reducing their absorption; administer other medications at least 1 hour before or 4-6 hours after XOLEGEL, Use caution in patients with hepatic insufficiency or biliary obstruction |
| Food/Dietary | No specific food interactions reported. However, grapefruit and grapefruit juice may increase systemic levels due to CYP3A4 inhibition; consider avoiding excessive consumption. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal studies have not revealed evidence of teratogenicity. Risk cannot be ruled out; use only if benefit outweighs potential fetal risk. |
| Fetal Monitoring | No specific monitoring required beyond routine prenatal care. Observe for local skin reactions. |
| Fertility Effects | No human data on fertility effects. Animal studies show no impairment of fertility. |
| Clinical Pearls | Apply sparingly to affected areas only; avoid use on large body surface areas due to potential systemic absorption. Concomitant use of CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase systemic exposure; monitor for adverse effects. Not recommended for use under occlusion or on mucous membranes. |
| Patient Advice | Wash hands before and after applying the gel. · Apply only to affected areas; avoid contact with eyes, mouth, or broken skin. · Do not use on large areas of skin or for prolonged periods without medical advice. · Report any signs of infection or severe irritation to your healthcare provider. · Do not cover treated areas with bandages or dressings unless directed by your doctor. |